The National Methadone Conference-2

American Association for the Treatment of Opioid Dependence
Washington, D.C. ~ April 13-16, 2003


Pre Conference Session 8:30 AM – 5:45 PM
April 12, 2003

Sharon Dow, MS
Joint Commission
Washington, DC
Joanne Page, MSW
Council On Accreditation
New York, NY
Walter Ginter
NAMA
Westport, CT
J. Thomas Payte, MD
Drug Dependence Associates
San Antonio, TX
Bettye Harrison, MSW, LISW
CARF Accreditation
Tucson, AZ
C. Todd Rosendale, MA
CSAT/Division of Pharmacologic Therapies
Rockville, MD
Herman Joseph, PhD
New York State Office of
Alcoholism and Substance Abuse Services
New York, NY
Joycelyn Sue Woods, MA
NAMA
New York, NY

NAMA would also like to thank our Faces of Advocacy: Alice Diorio, New England Alliance of Methadone Advocates; Robert Lubran, CSAT; Ira Marion, AECOM; Carmen Pearman, The MAG of Indiana; Valerie Robinson, DANYA; Rick Samson, FAVOR; Paul Samuels, Legal Action.

It is NAMA’s view that everyone who believes in methadone treatment is a potential methadone advocate. We encourage all supporters of methadone treatment, patient and non-patient, to become Certified Methadone Advocates (CMA) so that all energies directed toward the advancement of methadone treatment produce positive results.

This course fulfills the training requirement for certification as a Methadone Advocate. It is designed for non-clinicians, and involved eight hours of rigorous training. The course equips participants with the tools that they will need to succeed in the struggle to have methadone maintenance treatment universally accepted as the “gold standard” for addiction treatment.

With these goals in mind the course presentation is as follows:

  1. Addiction and Methadone – scientifically accurate yet in language understandable to the non-clinician.
  2. Regulations and Accreditation – explained by experts from CARF, COA and JCAHO who understand the systemic complexities.
  3. Faces of Advocacy – support for methadone treatment finds its source in both anticipated and unanticipated places in the community.
  4. The Certified Methadone Advocate (CMA) – the mechanism of certification and how it will professionalize those committed to advocacy.
  5. Methadone Stigma – a history of administrative and community prejudice directed at methadone patients, and analyses of possible solutions.

Candidates for certification must register with NAMA prior to the conference so that their Handbook may include information specific to their state.

Working a Conference
Jo. L. Sotheran, PhD
A short presentation on getting the most out of a conference, how to plan your time and networking skills.
(powerpoint)

NAMA would like to thank Robert Kovacik— for donating his skills and materials to videotape the day’s training.

Photo Album of the CMA Training

Similar Posts

  • Figure 3 The Methadone Molecule

    Admin 05/15/2023

       Contents          The Pharmacology of Opioids  Cont.      Back    Education Series Number 5.1  February 2001 (Revised)  Part 2 continued     Figure 3 The Methadone Molecule.  The two dimensional representation of the methadone molecule is very different from that of morphine. However, molecules are three dimensional and the methadone molecule bends into a structure that is very…

  • Accreditation, Advocacy and Patients in MAT

    Admin 10/31/2022

    James P. Connolly, CMA PA-NAMA and NAMA Newtown, PA Rebecca Ballard, CMA OK NAMA Tulsa, OK Carolyn Miranda, CMA NAMA SOCAL Fountain Valley, CA Changes in the service environment of MAT, expecially accreditation, are affecting relationships of patients, providers, and outside agencies. A panel of NAMA advocates will describe experiences with patient committees, staff advocacy…

  • CERTIFIED MEDICATION ASSISTED TREATMENT (MAT) ADVOCATE (CMA)-1

    Admin 06/23/2021

    The Basic Advocacy Training Session The training for certification includes a variety of topics to give advocates a well-grounded understanding of MAT, research, regulations and laws that protect MAT patients and programs. Medication Assisted Treatment  Basic clinical information about methadone and buprenorphine treatment. Regulations and Accreditation The federal regulations will be explained:  What they are and…

  • Focus On

    Admin 09/16/2021

    Issues To Focus On LAAM Manufacture to Be Discontinued August 23, 2003 Washington, D.C. Roxanne the manufacturer of LAAM has informed the FDA that manufacture of the medication is being discontinued. Distribution will continue until the inventory is depleted. Roxanne estimates this to be in early January 2004. The reason for the action is the…

  • What is NAMA

    Admin 06/14/2023

    NAMA IS COMMITTED TO: Promoting quality methadone maintenance treatment as the most effective modality for the treatment of heroin addiction.  Working to dispel the ignorance regarding MMT which plagues both treatment professionals and the general public.  Fighting discrimination perpetrated against methadone maintenance patients.  Struggling to destigmatize the treatment which has given us back our lives. …

  • Executive Report-1

    Admin 10/14/2022

    HEROIN ADDICTION – HOW METHADONE WORKS Carmen Arlt, Director of Chemical Dependency & Addictions, Porter-Starke Services and Director, The MAG Indiana The Munster Times Mon, 01 Sep 2003 Porter Starke Services’ Chemical Dependency and Addictions Program has a clear understanding of the dynamics involved in heroin addiction. While we do not dispense methadone, we believe…